Indication
Recurrent Metastatic Squamous Neck Cancer With Occult Primary
1 clinical trial
3 products
1 drug
Clinical trial
A Phase I Dose Escalation Study of the mTOR Inhibitor Everolimus (RAD001) and Erlotinib Concurrently With Radiation Therapy in the Re-Irradiation Setting for Head and Neck CancerStatus: Withdrawn, Estimated PCD: 2011-05-01
Drug
everolimusProduct
ErlotinibProduct
Microarray Analysis